secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2023-11-27T23:59:59+00:00
Accession:  0001370053-23-000069
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio licenses global rights to BDCA2 modulator antibody portfolio from Centessa for $7M upfront
--------------------------------------------------------------------------------

- Upfront cash payment of $7M ($4M license fee + $3M for GMP supply of ANB101).
- Centessa eligible for $10M milestone at first Phase 3 start and low single-digit royalties.
- Anaptys plans to file IND for ANB101 in H2 2024; ANB033 IND expected H1 2024.
- Reiterates year-end 2023 cash of $400–410M and cash runway through end of 2026.
- ANB101 targets BDCA2 on plasmacytoid dendritic cells for autoimmune/inflammatory diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005323000069/0001370053-23-000069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005323000069/anab-20231124.htm
  HTML page:      https://secwatch.observer/filing/0001370053-23-000069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer